TY - JOUR T1 - Effects of strontium ranilate and Hypericum perforatum extract on experimental colitis model in rats AU - Kurt, Atilla AU - Soylu, Sinan AU - Şahin Inal, Zeynep Deniz AU - Serin, Musa PY - 2018 DA - June Y2 - 2018 DO - 10.7197/223.v40i37154.390415 JF - Cumhuriyet Medical Journal JO - CMJ PB - Sivas Cumhuriyet University WT - DergiPark SN - 1305-0028 SP - 194 EP - 200 VL - 40 IS - 2 LA - en AB - Objective:In this study, we aimed to compare the healing effect of strontium ranilate(SR)and hypericum perfaratum (HPE) with the healing effect of prednisolone used inthe treatment of experimental colit in rats.Materialand Method: 30 wistar albino rats were used in the study. Ratswere randomly assigned to 5 consecutive groups consisting of 5 rats. Group 1,healthy rats, group 2 colitis but untreated rats. The rats in groups 3, 4, and5 had colitis and received 160 mg / kg SR, 1mg/kg prednisolone and HP extracts containing 0.3% hiperisine (250uq / 300 mg) by oral gavage, respectively for seven days. At the end of theseventh day, the colons of the rats were removed and histopathologicalexamination was performed. Results:The histopathological results of the HPE group were statistically worstincluding the control group. It was observed that the best results in thetreatment groups were SR group followed by prednisolone group, respectively.(P<0.05)Conclusion: Thisstudy concluded that SR was at least as effective as prednisolone in colitistreatment, but HPE exacerbate colitis-induced inflammation when received byorally KW - Strontium KW - Hypericum perforatum KW - colit CR - References1. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatuary bowel disease. Gastroenterogy 1994; 106(6): 1455-66. 2. Reimund JM, Wittersheim C, Dumont S, Muller CD, Kenny JS, Baumann R, et al. Increased production of tumour necrosis factor-alpha, interleukin-1 beta,and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn’s disease. Gut 1996: 39(5): 684-9.3. Stack WA, Mann SD, Roy AJ, Heath P, Sopwith M, Freeman J, et al. Randomised controlled trial of CDP571 antibody to tumour necrosis factor-alpha in Crohn’s disease. Lancet 1997; 349 (9051): 521-4.4. Rutgeerts P, D’Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 1999;117(4):761-9.5. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman Tet al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 study Group. New England journal of Medicine 1997;337(15):1029-35.6. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-𝜅B pathway in the treatment of inflammation and cancer. The Journal of Clinical Investigation 2001;107(2):135-142.7. Topal, F, Yonem O, Tuzcu N, Tuzcu M, Ataseven H, Akyol M. Strontium chloride: can it be a new treatment option for ulcerative colitis? Biomed. Research International 2014; 2014: 530687.doi:10.1155/2014/530687. 8. Collaert B, Fischer C. Dentine hypersensitivity: a review Endodontics & Dental Traumatology 1991;7: 145-152. 9. Autio KA, Scher HI, Morris HI. Therapeutic strategies for bone metastases and their clinical sequelae in prostate cancer Current Treatment Options in Oncology 2012; 13: 174-188.10. Yamaguchi M, Weitzmann MN. The intact strontium ranelate complex stimulates osteoblastogenesis and suppresses osteoclastogenesis by antagonizing NF-𝜅B activation Molecular and Cellular Biochemistry 2012; 359: 399-407.11. Buache E, Velard F, Bauden E. Effect of strontium substituted biphasic calcium phosphate on inflammatory mediators production by humanmonocytes Acta Biomateriali 2012; 8: 3113-3119.12. Bay top T. Medical plants used in Turkey. Therapy with plants in Turkey (past and present) 2nd ed. Istanbul: Nobel Medical Bookstore; 1999: 166-7.13. Mukherjee PK, Saritha GS, Suresh B. Antibacterial spectrum of Hypericum hookerianum. Fitoterapia 2001; 72: 558-60.14. Medina MA, Martínez-Poveda B, Amores-Sánchez MI, Quesada AR. Hyperforin: more than an antidepressant bioactive compound? Life Science 2006; 79(2): 105-11. 15. K. Mousavizadeh, R. Rahimian, G. Fakhfouri, et al. Antiinflammatory effects of 5-HT receptor antagonist, tropisetron on experimental colitis in rats. European Journal of Clinical Investigation2009; 39: 375–83.16. Chui CJ, Mc Ardle AH, Brown R, Scott HJ, Gurd FN. Intestinal mucosal lesion in low flow states. A morphological hemodynamic and metabolic reappraisal. Arch Surg 1970;101(4):478-83. 17. A. Geremia, P. Biancheri, P. Allan, G. R. Corazza, A. di Sabatino. Innate and adaptive immunity in inflammatory bowel disease Autoimmunity Reviews 2014; 13: 3–10. 18. P. Celerier, A. Richard, P. Litoux, B. Dreno. Modulatory effects of selenium and strontium salts on keratinocyte-derived inflammatory cytokines Archives of Dermatological Research 1995; 287(7) 680–682, 1995. 19. E. Buache, F. Velard, E. Bauden, Guillaume C, Jallot E, Nedelec JM, et al. Effect of strontiumsubstituted biphasic calcium phosphate on inflammatory mediators production by humanmonocytes Acta Biomaterialia 2012; 8 (8) 3113–3119. 20. Peksen ME, Kurt A, Soylu S, Tuzcu M, Bostancı ME, Mollaoglu MC, et al. Comparison of the healing effects of silver sulfodiazine cream 1% and the extract of Hypericum Perforatum on scald burn wound in a rat model. 2014; 3: 1-8. UR - https://doi.org/10.7197/223.v40i37154.390415 L1 - https://dergipark.org.tr/en/download/article-file/496275 ER -